Ellipses Pharma
Ellipses Pharma
Explore linked clinical trials.4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies | non-small cell lung carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-07-01 | NCT05443126 | |
| Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, neoplasm, skin disorder | Recruiting | Phase 1 / Phase 2 | 2026-06-22 | NCT05573126 | |
| Study to Evaluate the Safety and Tolerability of EP0042 | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-06-22 | NCT04581512 | |
| A Study to Evaluate the Safety and Tolerability of EP0089 | Solid Cancers; Solid Tumours | Not yet recruiting | Phase 1 / Phase 2 | 2025-06-22 | NCT07030478 |